Details for New Drug Application (NDA): 012126
✉ Email this page to a colleague
NDA 012126 describes ULO, which is a drug marketed by 3M and Takeda Pharms Usa and is included in two NDAs. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the ULO profile page.
The generic ingredient in ULO is febuxostat. There are twenty-six drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the febuxostat profile page.
The generic ingredient in ULO is febuxostat. There are twenty-six drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the febuxostat profile page.
Summary for 012126
| Tradename: | ULO |
| Applicant: | 3m |
| Ingredient: | chlophedianol hydrochloride |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SYRUP;ORAL | Strength | 25MG/5ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
